Abstract
N-Glycosylated substrates that undergo ER-associated degradation (ERAD) are often deglycosylated by the cytosolic peptide:N-glycanase (Ngly1) during their proteasomal degradation in the cytosol. Consequently, the presence of non- or deglycosylated forms of such proteins after treatment with proteasome inhibitors is widely used as evidence for cytosolic deglycosylation by Ngly1. However, in this study, the accumulation of nonglycosylated RTA∆m, a model ERAD substrate, was still observed in mouse cells lacking cytosolic de-N-glycosylating enzymes, when treated with proteasome inhibitors. It was found that RTA∆m is normally partially N-glycosylated, while the nonglycosylated form is rapidly degraded by proteasomes in the cytosol. Our results suggest that the occurrence of ‘nonglycosylated’ ERAD substrates upon treatment with proteasome inhibitors is not necessarily a clue for cytosolic deglycosylation.
Author supplied keywords
Cite
CITATION STYLE
Huang, C., & Suzuki, T. (2020). The occurrence of nonglycosylated forms of N-glycoprotein upon proteasome inhibition does not confirm cytosolic deglycosylation. FEBS Letters, 594(9), 1433–1442. https://doi.org/10.1002/1873-3468.13734
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.